Your browser is no longer supported. Please, upgrade your browser.
FUSN Fusion Pharmaceuticals Inc. weekly Stock Chart
Fusion Pharmaceuticals Inc.
Index- P/E- EPS (ttm)- Insider Own9.00% Shs Outstand41.68M Perf Week-2.34%
Market Cap507.00M Forward P/E- EPS next Y-0.25 Insider Trans0.00% Shs Float31.91M Perf Month1.21%
Income- PEG- EPS next Q-0.22 Inst Own76.00% Short Float0.76% Perf Quarter-0.79%
Sales- P/S- EPS this Y-38.90% Inst Trans-6.92% Short Ratio7.19 Perf Half Y-
Book/sh7.35 P/B1.70 EPS next Y79.30% ROA- Target Price- Perf Year-
Cash/sh7.20 P/C1.74 EPS next 5Y- ROE- 52W Range11.50 - 19.00 Perf YTD-26.47%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-34.21% Beta-
Dividend %- Quick Ratio55.90 Sales past 5Y- Gross Margin- 52W Low8.70% ATR0.62
Employees41 Current Ratio55.90 Sales Q/Q- Oper. Margin- RSI (14)47.72 Volatility5.88% 5.24%
OptionableNo Debt/Eq0.00 EPS Q/Q-189.00% Profit Margin- Rel Volume0.39 Prev Close12.89
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume33.71K Price12.50
Recom1.50 SMA20-3.13% SMA50-0.25% SMA200-6.55% Volume13,270 Change-3.03%
Jul-21-20Initiated Wedbush Outperform $25
Jul-21-20Initiated Jefferies Buy $25
Jul-21-20Initiated Cowen Outperform
Nov-26-20 12:36AM  
Nov-12-20 04:10PM  
Nov-10-20 07:00AM  
Nov-02-20 04:10PM  
Oct-27-20 03:30PM  
Oct-11-20 09:30AM  
Sep-29-20 04:15PM  
Sep-27-20 10:18AM  
Sep-10-20 09:00AM  
Aug-11-20 07:25AM  
Aug-05-20 08:00AM  
Jul-14-20 09:30AM  
Jul-10-20 05:13PM  
Jun-25-20 10:39PM  
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.